Skip to main content

Advertisement

ADVERTISEMENT

news

News
03/26/2022
Cathy Eng, MD, FACP, FASCO, argued for VEGF therapy versus anti-EGFR inhibition in a debate with Dr Kasi at the 2022 GDU GI conference in New York, NY.
Cathy Eng, MD, FACP, FASCO, argued for VEGF therapy versus anti-EGFR inhibition in a debate with Dr Kasi at the 2022 GDU GI conference in New York, NY.
Cathy Eng, MD, FACP, FASCO,...
03/26/2022
Oncology
News
03/26/2022

Alexa Stoia

Alexa Stoia
Pashtoon M. Kasi, MD, MS, argued for EGFR inhibitors as a superior first-line treatment vs VEGF in a debate with Cathy Eng, MD, FACP, FASCO, at the 2022 Great Debates and Updates in GI Malignancies meeting.
Pashtoon M. Kasi, MD, MS, argued for EGFR inhibitors as a superior first-line treatment vs VEGF in a debate with Cathy Eng, MD, FACP, FASCO, at the 2022 Great Debates and Updates in GI Malignancies meeting.
Pashtoon M. Kasi, MD, MS, argued...
03/26/2022
Oncology
News
09/26/2020
At the Great Debates & Updates in GI Malignancies, Scott Kopetz, MD, PhD, participated in a lively debate on comprehensive molecular panel testing for GI Cancers, and spoke in favor of it.
At the Great Debates & Updates in GI Malignancies, Scott Kopetz, MD, PhD, participated in a lively debate on comprehensive molecular panel testing for GI Cancers, and spoke in favor of it.
At the Great Debates & Updates...
09/26/2020
Oncology
News
08/10/2020
At the virtual 2020 Great Debates and Updates in GI Malignancies, experts in the oncology space will discuss and debate advancements in therapies for GI cancers.
At the virtual 2020 Great Debates and Updates in GI Malignancies, experts in the oncology space will discuss and debate advancements in therapies for GI cancers.
At the virtual 2020 Great...
08/10/2020
Oncology

Advertisement